BEXAROTENE

SynDRA canonical compound SYN0003202 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	RXRG
Mechanism of action	Retinoid receptor agonist
Indication	cutaneous T-cell lymphoma (CTCL)
Disease area	hematologic malignancy

All known targets

LGD 1069
targretin
targretyn
targrexin
Bexaroteno
LG-100069
LG100069
LGD-1069
LGD1069
NSC-747528
Targretin
Targretine
Bexarotenum
Targret
Targretyn
Targrexin
Bexarotene [USAN]
Elan brand of bexarotene;Ligand brand of bexarotene
LG 1069
LG1069
LG69 compound
Targretin (TN)
Targretin-gel
Bexarotene (USAN/INN)
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
3-methyl-TTNEB
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid
NSC 747528
CHEMBL1023